EXOSENS Stock Accelerates to €49.40 (+4%), Consolidating Its Weekly Gain of +11.39%
The detection and imaging technology specialist shows strong progress at midday on Monday, October 27. This momentum is based on the release of better-than-expected results for the first nine months of 2025, in a highly favorable defense market context. However, trading remains moderate, with 0.16% of the capital traded since opening, suggesting that this rebound stems from targeted rather than exceptional demand.
Strong Opening Performance
Exosens has gained 4% since the opening, crossing the €49 mark to trade at €49.40. This increase brings the stock close to its immediate resistance level of €49.30, indicating a strong buying momentum. Over a longer period, the trend is clearly positive. Over the past seven days, the stock has risen by 11.39%, significantly outperforming the CAC 40, which only recorded a 0.1% increase during this session. The annual context is even more favorable, as over the past year, the group has seen a 152.7% increase compared to only 9.82% for the Paris index. The last three months have also been beneficial, with an increase of 27.32%, corroborating a bullish underlying movement. This Monday, Exosens published its results for the first nine months of the year, revealing a revenue of €327.8 million, up 23.2% compared to the same period last year. This growth is particularly supported by the Amplification segment, which grew by 20.6% thanks to increasing demand for image intensifier tubes for night vision applications in the defense sector. The Detection and Imaging segment also shows strong dynamics with a 26.2% increase. Profitability has improved significantly: the adjusted gross margin increased by 28.7% to €168 million, bringing the margin rate to 51.2%, an improvement of 221 basis points. This margin expansion, especially in the Amplification segment (+33.1%), reflects both volume effects and operational optimizations.
Maintained Guidance for 2025
Exosens maintains its guidance for the year 2025, confirming previously announced ambitions. The group anticipates revenue growth in the upper range of 15 to 20%, while adjusted EBITDA is expected to increase in the lower range of 20 to 25% compared to 2024. For the period 2024-2026, adjusted EBITDA is expected to grow annually compounded in the upper range of 15 to 20%, with a cash flow conversion ratio projected between 70 and 75%. The group also continues its strategy of selective external growth, while maintaining a financial leverage ratio of about 2 times. The acquisition strategy is intensifying. Recently, Exosens completed the acquisitions of Noxant in March, NVLS in July, and Phasics in October, thus strengthening its technological portfolio in the critical areas of night vision and imaging. Concurrently, the group has opted to divest its Microwave Amplification business, refocusing on segments offering the best growth prospects and profitability. The defense market remains extremely supportive for companies in the sector, bolstered by persistent geopolitical tensions and increasing military budgets in many regions. Exosens directly benefits from this dynamic, with a large part of its portfolio exposed to equipment and technologies for critical defense and security applications.
Technical Overview
Technically, Exosens is now well above its main moving averages. The 50-day moving average is at €42.68, while the 200-day moving average has risen to €36.70, confirming a bullish underlying trend. The Relative Strength Index (RSI) is positioned at 61, indicating a positive momentum without excessive overextension. The stochastic signal displays a buy recommendation. The upper Bollinger Band is set at €49.58, very close to the current price, while the lower band is at €41.92. The MACD presents a slightly negative histogram at -0.06, suggesting a possible short-term consolidation despite the positive signal line. The Average True Range at 1.53 points indicates a 1-month volatility measured at 17.56%.
